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Anna Cereda1 and John C Carey2*Abstract
The trisomy 18 syndrome, also known as Edwards syndrome, is a common chromosomal disorder due to the
presence of an extra chromosome 18, either full, mosaic trisomy, or partial trisomy 18q. The condition is the
second most common autosomal trisomy syndrome after trisomy 21. The live born prevalence is estimated as
1/6,000-1/8,000, but the overall prevalence is higher (1/2500-1/2600) due to the high frequency of fetal loss and
pregnancy termination after prenatal diagnosis. The prevalence of trisomy 18 rises with the increasing maternal age.
The recurrence risk for a family with a child with full trisomy 18 is about 1%.
Currently most cases of trisomy 18 are prenatally diagnosed, based on screening by maternal age, maternal serum
marker screening, or detection of sonographic abnormalities (e.g., increased nuchal translucency thickness, growth
retardation, choroid plexus cyst, overlapping of fingers, and congenital heart defects ). The recognizable syndrome
pattern consists of major and minor anomalies, prenatal and postnatal growth deficiency, an increased risk of
neonatal and infant mortality, and marked psychomotor and cognitive disability. Typical minor anomalies include
characteristic craniofacial features, clenched fist with overriding fingers, small fingernails, underdeveloped thumbs,
and short sternum. The presence of major malformations is common, and the most frequent are heart and kidney
anomalies. Feeding problems occur consistently and may require enteral nutrition.
Despite the well known infant mortality, approximately 50% of babies with trisomy 18 live longer than 1 week and
about 5-10% of children beyond the first year. The major causes of death include central apnea, cardiac failure due
to cardiac malformations, respiratory insufficiency due to hypoventilation, aspiration, or upper airway obstruction
and, likely, the combination of these and other factors (including decisions regarding aggressive care). Upper airway
obstruction is likely more common than previously realized and should be investigated when full care is opted by
the family and medical team.
The complexity and the severity of the clinical presentation at birth and the high neonatal and infant mortality
make the perinatal and neonatal management of babies with trisomy 18 particularly challenging, controversial,
and unique among multiple congenital anomaly syndromes. Health supervision should be diligent, especially in
the first 12 months of life, and can require multiple pediatric and specialist evaluations.Disease names and synonyms
Trisomy 18, Edwards syndromeDefinition
The trisomy 18 syndrome, also known as Edwards syn-
drome, is a common autosomal chromosomal disorder
due to the presence of an extra chromosome 18. The
first reported infants were described in 1960 by Edwards
et al. and Smith et al. [1,2]. The syndrome pattern
comprises a recognizable pattern of major and minor* Correspondence: john.carey@hsc.utah.edu
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distribution, and reproduction in any mediumanomalies, an increased risk of neonatal and infant mor-
tality, and significant psychomotor and cognitive disabil-
ity. The main clinical features represent the clues for the
diagnosis in the perinatal period and include prenatal
growth deficiency, characteristic craniofacial features,
distinctive hand posture (overriding fingers, see Figure 1),
nail hypoplasia, short hallux, short sternum, and major
malformations (particularly involving the heart). The
demonstration of an extra chromosome 18, or less com-
monly a partial trisomy of the long arm of chromosome
18, on the standard G-banded karyotype allows for con-
firmation of the clinical diagnosis. A small portion of
patients (less than 5% in population studies cited below)
have mosaicism of trisomy 18; they show an extremely
variable phenotype.ntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Figure 1 A boy with full trisomy 18 in early infancy and at
one year. Note the characteristic hand feature with the over-riding
fingers, the tracheostomy, and his engaging smile. He is now over 2
years of age and is quite stable medically, gaining weight, sitting up,
and participating in the many activities of his family.
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Trisomy 18 is the second most common autosomal tri-
somy syndrome after trisomy 21.
Several population studies have been performed in
different countries including Australia, Europe and
North America that estimate the prevalence of trisomy
18 [3-9]. On the basis of these investigations the live
birth prevalence of trisomy 18 ranges from 1/3600 to
1/10,000 with the best overall estimate in liveborns as
1 in 6,000 [3,6].
It is well known that trisomy 18 pregnancies have a
high risk of fetal loss and stillbirth [10,11]; furthermore,
currently most diagnoses are made in the prenatal
period based on screening by maternal age or maternal
serum marker screening and amniocentesis, followed by
pregnancy termination in a significant percentage of
cases [9]. Because of this, the overall prevalence (consid-
ering stillborn infants, terminated pregnancies, and live-
born infants) of trisomy 18 would be expected to be
higher than live birth prevalence. A seminal population
study in the United Kingdom in 1996 reported an overall
prevalence of 1/4272 and a liveborn prevalence of
1/8333 [4]; the overall frequency detected in Hawaii
from a similar study was 1/2123 with a liveborn fre-
quency of 1/7900 [5]. Recent investigations showed an
increase of the overall prevalence of trisomy 18 over
the last 20 years due to increased maternal age [9]; how-
ever, a decrease of liveborn frequency was observed
because of the increased use of prenatal diagnosis and
the high rate of pregnancy termination after the prenatal
diagnosis [7,9]. In these more recent studies overall
prevalence was estimated as 1/2500 in United States [7]
and as 1/2600 in United Kingdom [9]; liveborn preva-
lence was estimated as 1/8600 in United States [7] and
as 1/10,000 in United Kingdom [9].The prevalence at birth is higher in females compared
to males (F:M %, 60.4), but this discordance is not
present if the sex ratio is calculated among fetuses elec-
tively terminated (F:M % 48:51.) [7]. Moreover the fre-
quency of fetal loss is higher for males compared to
females [10,11]. Furthermore, liveborn females showed
better survival compared to males [4,6].
Etiology and pathogenesis
The trisomy 18 (or Edwards syndrome) phenotype results
from full, mosaic, or partial trisomy 18q [4,12-15].
Complete or full trisomy 18 is the most common form
(about 94% of cases); in this situation every cell contains
three entire copies of chromosome 18.
Most authorities have suggested that the extra
chromosome is present because of nondisjunction. In
parent-of-origin analyses the extra chromosome is most
often of maternal origin, the result of an error during
the segregation of chromosomes in meiosis or postzygo-
tic mitosis. About 50% of the nondisjunctional errors
in oogenesis occur in meiosis II, unlike other human
trisomies where the malsegregation is more frequent in
meiosis I [16-19]. In the minority of cases in which the
extra chromosome has a paternal origin, the error is
the result of a postzygotic error. The cause of non-
disjunction is unknown. Recently a higher prevalence
of methylene tetrahydrofolate reductase gene (MTHFR)
polymorphisms in mothers of trisomy 18 fetuses com-
pared with other groups was reported [20] but this result
has not been replicated.
As in the other common autosomal trisomies, the fre-
quency of nondisjunctional errors increases with advan-
cing maternal age. Savva et al., studied the maternal age
specific live birth prevalence of trisomy 18: the fre-
quency is constant until age 30, then increases exponen-
tially before beginning to become constant again at age
45 [21]. The observed increased overall prevalence of tri-
somy 18 in the last years is likely due to changes in the
maternal age distribution during this time period [9,21].
A small positive association of paternal age with trisomy
18, similar to that observed in Down syndrome, has also
been observed [22].
In individuals carrying mosaic trisomy 18 (less than
5% of cases), both a complete trisomy 18 and a normal
cell line exist. The phenotype is extremely variable, ran-
ging from complete trisomy 18 phenotype with early
mortality to apparently phenotypically normal adults, in
which the mosaicism is detected after the diagnosis
of complete trisomy 18 in a child [23-27]. There is no
correlation between the percentage of trisomy 18 cells in
either blood cells or skin fibroblasts and the severity of
clinical manifestations and intellectual disabilities [24].
Tucker et al., [24] provided a comprehensive review of
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cent paper and reported on 3 new cases.
In the partial trisomy form only a segment of the
chromosome 18 long arm is present in triplicate, often
resulting from a balanced translocation or inversion car-
ried by one parent. This type of trisomy accounts for ap-
proximately 2% of cases presenting with the Edwards
phenotype. The location and the extent of the triplicated
segment and the possible associated deletion of genomic
material due to unbalanced translocation can explain the
variable phenotype associated with partial trisomy [12].
The region of long arm of chromosome 18 extending
from q11.2 has been proposed as the critical region for
trisomy 18 phenotype, but some controversial data have
been reported [28,29]. Boghosian-Sell et al. hypothesized
the presence of two critical regions along the long arm
of chromosome 18: one proximal region lying within
18q12.1-18q21.2 and another one more distal lying
within 18q22.33-18qter [29]. The same authors reported
two patients with trisomy of 18q11.2 to terminus not
showing the complete pattern of trisomy 18; the patients
had better survival and growth. Therefore, some role for
genes on the short arm or 18q11.1 region in the expres-
sion of full phenotype cannot be excluded.
Antenatal diagnosis
Currently in the North America and Europe most cases
of trisomy 18 are prenatally diagnosed, based on screen-
ing by maternal age, maternal serum marker screening,
or detection of sonographic abnormalities during the
second and third trimester [9,30]. The prenatal diagnosis
of trisomy 18 leads to the decision of pregnancy termin-
ation in 86% of cases [9]. Knowledge of the survival
where termination is not chosen is important as well,
because the parents will seek this information and this
knowledge can influence the management at the time of
delivery and in the neonatal period [12].
First trimester non invasive screening based on mater-
nal age, serum markers and sonographic “soft markers”
demonstrated high sensitivity for diagnosis of trisomy 18
[31-33], and it is now being applied routinely. The levels
of human chorionic gonadotropin, unconjugated estriol,
and alpha-fetoprotein are significantly lower in pregnan-
cies with trisomy 18 compared to normal pregnancy
[31]. The most common soft sonographic markers
detected in the late first/early second trimester are the
increased nuchal translucency thickness and the absence
or hypoplasia of the nasal bone [34-36]; the screening by
assessment of nuchal fold and nasal bone identifies
66.7% of cases with trisomy 18 (and 13) [36]. By includ-
ing the evaluation of reversed flow in the ductus venosus
and the tricuspid valve regurgitation, the detection rate
increases to 83.3% [36]. Furthermore, some structural
anomalies can be detected by ultrasound screeningduring the first trimester; the most common are om-
phalocele (21%), abnormal posturing of the hands (6%),
megacystis (4%) and abnormal four-chamber view of the
heart (4%) [35]. Early-onset fetal growth retardation can
be detected in 26% of cases [36], but becomes more evi-
dent in the second trimester [30,37]. The detection
rate of combined late first trimester screening (nuchal
translucency, pregnancy-associated plasma protein and
free beta-hCG) and second trimester quadruple screen-
ing (serum alpha-fetoprotein, total hCG, unconjugated
estriol and inhibin A) is at least 78% sensitive [32,33].
Many studies have been published in the last 15 years
regarding the prenatal pattern of ultrasound findings in
trisomy 18 fetuses in the second and third trimester
[30,35-39]. One or more sonographic anomalies are
detected in over 90% of fetuses; two or more abnormal-
ities are present in 55% of cases [38]. The prenatal sono-
graphic pattern of trisomy 18 is characterized by growth
retardation, polyhydramnios, “strawberry-shaped” cra-
nium (brachycephaly and narrow frontal cranium), chor-
oid plexus cyst, overlapping of hands fingers (second
and fifth on third and fourth respectively), congenital
heart defects, omphalocele, and single umbilical artery
[30,35-39]. The prevalence of growth retardation and
polyhydramnios increases with gestational age: 28% and
29% in the second trimester and 87% and 62% in the
third trimester, respectively [37]. More than 30% of
fetuses show hands abnormalities [39], and one third of
cases have a single umbilical artery [37]. Furthermore,
the mothers often noted a decrease in fetal movement
compared to their normal pregnancies [37]. Choroid
plexus cyst (CPC) is detected in about 50% of trisomy 18
fetuses [39]; in the most of cases (80-90%) it is asso-
ciated with other sonographic anomalies [37,39], but in
a small percentage of pregnancies (11% according to
Cho et al. 2010) carrying trisomy 18 fetus, CPC can be
the only abnormality detected at ultrasound screening.
Choroid plexus cyst can be also a transitory finding in
normal fetuses; it has been reported that, among fetuses
that show CPC at second trimester sonographic screen-
ing, only about 5% have trisomy 18 [37,40,41]. Because
of these reasons, there is not a clear consensus in the
medical literature on whether to offer amniocentesis
after the discovery of choroid cyst, particularly when it is
an isolated finding [37,42-46].
Trisomy 18 pregnancies have a high risk of fetal loss
and stillbirth [10,11,37]. The probability of survival to
term increases with the increase of gestational age: 28%
at 12 weeks, 35% at 18 weeks and 41% at 20 weeks [10].
Fetal losses are uniformly distributed throughout gesta-
tion after 24 weeks without a clustering of fetal demises
at a particular gestational age [11,37]. Cases detected by
abnormal sonographic findings are more likely to result
in a miscarriage or stillbirth [37]. Furthermore, the
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twofold according to Niedrist et al., [47]) for males com-
pared to females [10,47].
Genetic counseling
When prenatal or neonatal diagnosis of trisomy 18 is
made, the counseling of the family should be realistic,
but not desolate. The parents can find it difficult to
accept the lack of certainty of the newborn situation,
but they have to be prepared for both the probability
of death and the possibility of living [48]. Because the
parents have to make practical decisions concerning
resuscitation, surgery and life support, all options for
newborn management should be explained. The com-
plex issues regarding perinatal management are covered
in more detail below.
Facilitating the family getting in touch with family sup-
port groups can be helpful: they can share experiences,
thoughts and concerns regarding health problems of
their children, and daily situations that they are coping
with. Table 1 shows the known support groups in North
America, Europe, Japan, and Australia.
The recurrence risk, for a family with a child with
complete trisomy 18 is usually stated as 1% [12]. Paren-
tal mosaicism has been reported in a few cases [24-27].
Furthermore, recurrence of different trisomies in the
same family has been reported [49]. Empirically calcu-
lated risks suggest that the recurrence risk seems to
be less than 1%, but higher than the age-specific back-
ground risk [50,51]. The recurrence risk in families
with partial trisomy 18 could be higher compared with
full trisomy 18, depending on the presence of a genomic
rearrangement (translocation or inversion) in one of
the parents.
Clinical description
The clinical pattern of trisomy 18 is characterized by
prenatal growth deficiency, specific craniofacial featuresTable 1 International parent support groups for trisomy 18
Country Support Group
Australia SOFT of Australia
Europe Chromosome 18 Registry and Research Society (E
France Valentin APAC Association de Porteurs d'Anomalie
Germany LEONA e.V. - Verein für Eltern chromosomal gesch
Ireland SOFT of Ireland
Italy SOFT Italia
Japan The Trisomy 18 Support Group
United Kingdom SOFT of United Kingdom
United States USA Support Group SOFT
United States Trisomy 18 Foundation
United States The Chromosome 18 Registry and Research Socieand other minor anomalies, major malformations, and
marked psychomotor and cognitive developmental delay.
The growth delay starts in prenatal period and con-
tinues after the birth, and most of the time is asso-
ciated with feeding problems that may require enteral
nutrition. Specific growth charts for trisomy 18 are
available [49] and are published on the SOFT US and
UK web pages (see Table 1) for printing and placement
in the child’s chart. Postnatal onset microcephaly is usu-
ally present.
Typical craniofacial features include dolichocephaly,
short palpebral fissures, micrognathia, (see Figure 1)
external anomalies of the ears, and redundant skin at
the back of the neck.
Other characteristic clinical findings are the clenched
fist with overriding fingers (index finger overlapping the
third and 5th finger overlapping the 4th –see Figure 1),
which is particularly distinctive, small fingernails, under-
developed thumbs, short sternum, and club feet. Pres-
ence of major malformations is common, and any organ
and system can be affected. Structural heart defects
occur in over 90% of infants. Table 2 summarizes the
most common major (medically significant) malforma-
tions detected in trisomy18 from various sources.
Differential diagnosis
The clinical pattern of trisomy 18 is quite well-defined,
and it is rarely misdiagnosed [12]. There are some over-
lapping features with Pena-Shokeir syndrome type 1 or
syndromes with fetal akinesia sequence (because of poly-
hydramnios and joint contractures including overriding
fingers), with distal arthrogryposis type 1 (because of
the similar finger positioning) and with CHARGE syn-
drome (because of the overlapping of major malfor-
mations). The not well characterized and co-called
condition known as pseudotrisomy 18 syndrome [53]













Table 2 Common major structural malformations in the trisomy 18 syndrome
Frequency Organ/System Prevalent type of malformation
Common (>75%) heart septal defects, patent ductus arteriosus, and polyvalvular disease
Frequent (25-75%) genitourinary horseshoe kidney
Less frequent (5-25%) gastrointestinal omphalocele, esophageal atresia with tracheo-esophageal fistula,
pyloric stenosis, Meckel diverticulum
central nervous system cerebellar hypoplasia, agenesis of corpus callosum, polymicrogyria,
spina bifida
craniofacial orofacial clefts
eye microphthalmia, coloboma, cataract, corneal opacities
limb radial aplasia/hypoplasia
From Jones [52], Baty et al. [49].
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Survival after birth and neonatal management
Perinatal and neonatal management of fetuses and new-
born diagnosed with trisomy 18 is multifaceted issue for
a variety of reasons: the complexity and, most of the
time, the severity of the clinical presentation at birth; the
need of parents and care providers to urgently make
decisions in care of the baby; the inevitable ethical impli-
cations due to the well known high neonatal and infant
mortality, and the significant developmental disability
in the surviving children that characterize this unique
(together with trisomy 13) condition.
There is a high percentage of fetuses dying during
labor (38.5%), and the preterm frequency (35%) is higher
compared to general population [30]. An increased inci-
dence of cesareans has been reported [4,54], even if in
the previous obstetric literature avoidance of delivery by
cesarean was recommended [55,56].
The first study about postnatal survival of children
with trisomy 18 was published in 1967: Weber reported
a mean survival of 70 days [57]. Most of the ensuing
population studies showed a shorter survival, likely be-
cause, with prenatal and neonatal diagnosis, it is now
possible to diagnose many cases, which would have died
prior to detection in the past [3].
Most recent studies report a median survival of 3-14.5
days, a percentage of survival at 24 hours of 60%-75%,
at 1 week of 40%-60%, at 1 month of 22%-44%, at
6 months of 9%-18%, and after 1 year of 5%-10%
[3,4,6,12,13,15,49,54,58-62]. To summarize, approximately
50% of babies with trisomy 18 live longer than 1 week,
and 5-10% of children survive beyond the first year.
Because these figures document that 1 in 10 to 1 in 20
babies live to their first birthday, the commonly used
term, “lethal abnormality”, is inaccurate, misleading, and
inappropriate [12].
The major causes of death are sudden death due
to central apnea, cardiac failure due to cardiac mal-
forxmations and respiratory insufficiency due to
hypoventilation, aspiration, upper airway obstruction or,
likely, the combination of these and other factors[4,12,13,15,49,54,58,59,63-65]. A recent study reported
a >100 times higher risk of mortality in neonatal period
and in the first years of life for children with trisomy 18
compared to infants born without birth defects [8].
Upper airway obstruction is likely more common than
previously realized and should be investigated when
full care is opted by the family and medical team. The
factors underlying the potential of survival are not
known; the presence of heart defects does not seem
to affect long-term survival [6]. However a recent trend
toward consideration of performing cardiac surgery
may alter that premise as surgery may play a role in pre-
venting pulmonary hypertension, a point not investi-
gated in determining the notion that heart defects do
not affect survival [6]. A longer survival for females
compared to males has been reported, as in the prenatal
period [4,6].
Because of the elevated risk of mortality in the first
month of life and the presence of significant develop-
mental disability in the surviving children, historically
there has been a consensus among care providers that
trisomy 18 be considered a condition for which non
intervention in the newborn was indicated [65,66].
Nevertheless, the most recent American Academy of
Pediatrics neonatal resuscitation guidelines omit trisomy
18 from the list of examples of conditions for which
resuscitation is not indicated [67]. A recent survey of
the opinion of American neonatologists on newborn
care of trisomy 18 infants reported that 44% would
intervene mostly because of parental wishes to support
the baby [68].
A recent Japanese study documented the survival rate
in a group of trisomy 18 newborn to which intensive
care were offered: the median survival time (152.5 days)
and survival rate at 12 months [25%] were higher com-
pared to those reported in the previous studies, but the
survival over 2 years (4%) was similar to the 5-10% usu-
ally reported as 1-year survival rate [54]. To our know-
ledge this is the only study that addresses the question
of infant survival if full intervention (short of cardiac
surgery) is offered.
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physiology to death in patients who had intensive treat-
ment; they distinguish between underlying factors
associated with death and final modes of death. The
common underlying factors associated with death were
congenital heart defects and heart failure, and pul-
monary hypertension. On the other hand, the final
modes of death were sudden cardiac or cardiopulmonary
arrest and events related to progressive pulmonary
hypertension [54]. From these observations, it becomes
clear that apnea and withdrawal of treatment could be
considered the major cause of death when a patient with
trisomy 18 was managed with purely comfort care.
When a patient with trisomy 18 has intensive treatment,
the common causes of death are altered, and survival
does increase.
The senior author had pointed out in an Editorial [69]
in 2006 that there existed a dire need to have a dialogue
regarding the ethical issues surrounding the manage-
ment and care of infants and children with trisomy 18.
Such a dialogue seems to be occurring in recent years:
the publication of the McGraw and Perlman paper [68]
mentioned above and the Ethics Rounds, a Special Art-
icle in Pediatrics in 2011 [70], both discuss the key
themes and controversies that needed current discus-
sion. The former paper indicated that the majority of
neonatologists polled in the study would not resuscitate
a newborn in the delivery room who had trisomy 18 and
a heart defect. The authors stated a concern about a
trend away from the “best interest of the child” standard
and towards parental opinion. In the more recent
Special Article two neonatologists and a parent discuss
their views on the management of a baby with trisomy
18 and a heart defect surrounding the decision to have
cardiac surgery [70]. While the doctors and the parent
disagreed on many points, one of the doctors and the
Editor state that “deference to the parents” is generally
the best course (unless the child is “suffering” from the
ongoing treatment) in situations of unclear outcome.
These papers and the published responses to them in
Pediatrics suggest that a dialogue is in fact now occurring.
Another recently published paper by Wilfond and Carey
[71], a case-based discussion of the issues and themes
involved in the management of trisomy 18 (and related
conditions), also illustrates this point of an emerging dia-
logue. The reader is referred to these papers for further
discussion of the relevant issues.
One of the key themes at the center of the controversy
is the question of so-called “quality of life” of children
and their families when a child has trisomy 18. We will
discuss this issue in the Unresolved Questions section
below as little data exist in the scientific literature on
this topic.Growth and feeding
Prenatal growth retardation is one of the most frequent
prenatal finding in trisomy 18 [30,35-39]; the mean birth
weight is 1700-1800 g at a mean gestational age of 37
weeks [4,54]. Weight and height continue to be below
the third centile in the postnatal period; growth charts
specific for the condition has been published [49] and
are available on the SOFT web pages for the both the
US and UK support groups (see Table 1). Head circum-
ference also tends to be below the third centile [12].
Most of the children have feeding difficulties that often
require tube feeding in the neonatal period or placement
of gastrostomy in the older children (at average age of 8
months) [49]. Both sucking and swallowing problems
can be present. Usually the skill of oral feeding if
achieved is achieved in infancy, and not later [12,49].
If it is unclear if an infant can or cannot protect her
airway, a swallow study can be performed to determine
the safety of oral feedings.
Gastroesophageal reflux is a significant medical prob-
lem because of both its high prevalence and its
potential consequences, like irritability, recurrent pneu-
monia and aspiration [12]. Aspiration due to gastroeso-
phageal reflux or during feeding is included among the
causes of early death [4,12,13,49,54,58,59,61-63].
Gastrointestinal malformations, such as esophageal
atresia with tracheo-esophageal fistula, occur with
increased frequency but are not a common feature in tri-
somy 18; pyloric stenosis has been reported and should
be considered in the older infant with vomiting [12]. Oc-
casionally the newborn with trisomy 18 can have orofa-
cial clefts that may contribute to feeding problems [12].
Cardiovascular
Larger series of infants with the syndrome show that
80%-100% of patients with trisomy 18 have congenital
structural heart defects; the most common cardiac
anomalies are ventricular and atrial septal defects, patent
ductus arteriosus and polyvalvular disease [12,72-74].
The majority of the malformations are unlikely to pro-
duce neonatal death; this is one of the reasons why the
cardiac defect is usually regarded as not causing the
early infant mortality. A more complex malformation
(double-outlet right ventricle, endocardial cushion de-
fect, or left-sided obstructive lesion) is present in about
10% of cases [12], and then the cardiac defect could play
a role in early mortality.
The role of cardiac malformations in causing early
death is controversial. Some studies reported that the
presence of heart defect does not negatively affect the
survival [6] and that the cardiac problems are not impli-
cated in the deaths in most of patients [4]. Based on
these data, cardiac surgery in the neonatal period is
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18 children. However, in other studies heart failure and
early development of pulmonary hypertension induced
by heart defects were found to play a significant role in
early death [69,74-76].
Traditionally, heart defects in trisomy 18 patients have
been managed conservatively. Recent studies, however,
showed that most patients (82-91%) with trisomy 18 can
survive palliative and corrective heart surgeries, suggest-
ing that heart surgery can be considered even in patients
with trisomy 18 [76-79] (see “Health supervision and
management of medical problems” for more details).
Respiratory
Respiratory problems are one of the most common
causes of death in trisomy 18 [4,12,49,54,58,59,61,62].
Pure respiratory problems, such as upper airway ob-
struction (in some case due to a laryngomalacia or tra-
cheobronchomalacia) and central apnea, can act
together with other problems of different origin, like
early–onset pulmonary hypertension, feeding difficulties,
recurrent aspirations and gastroesophageal reflux, lead-
ing to a severe respiratory symptoms [3,4]. Obstructive
sleep apnea may be a more common finding in older
infants [12] than realized.
Ophthalmologic
Many ocular findings have been reported in patients
with trisomy 18, although major ocular defects are
present in a small group of children (less than 10%) [80].
Occasionally, children with trisomy 18 can show anom-
alies such as a cataract or corneal opacities [81,82]. Short
palpebral fissures, visual acuity abnormalities, and
photophobia are common findings and underscore the
need for ophthalmology assessment in older infants [12].
Photophobia is very common in children with trisomy
18 and requires sunglasses when going outside the
home; it likely represents one reason why older infants
experience unexplained irritability.
Ears and hearing
Structural ear anomalies, such as meatal atresia and
microtia, are occasionally present. The features of exter-
nal ear are characteristic: the ear is small with a small
lobule, the helix is unfolded, simple and sometimes
attached to the scalp (cryptotia) [12]. The ear canal is
usually small making audiology screening sometimes
challenging. A wide spectrum of middle and internal ear
abnormalities has been described. Moderate to severe
sensorineural hearing loss can also be present [12].
Musculoskeletal
Major malformations of limb occur in 5-10% of patients,
including radial aplasia and other preaxial limb defects.About 50% of babies show positional foot deformities,
both talipes equinovarus and calcaneovalgus. In addition,
contractures of other joints can be present explaining
why trisomy 18 is sometimes the basis for a neonate la-
beled artrogryposis. Overriding fingers (second and fifth
on third and fourth respectively-see Figure 1) represent
one of the important diagnostic clues, often detected
sonographically in the prenatal period. Scoliosis is com-
mon in older children; usually it is not related to verte-
bral structural abnormalities and may progress between
5 and 10 years of age [12].
Genitourinary
Horseshoe kidney is common finding in trisomy 18
(about two-thirds of patients). An increased frequency
of urinary tract infections has been observed, perhaps
due to structural defects [31]. Otherwise, renal failure is
uncommon [12].
Neoplasia
Trisomy 18 patients have an increased risk to develop
some neoplasia, including Wilms tumor and hepatoblas-
toma [83]. At least 8 cases of Wilms tumor in trisomy
18 children have been reported in the medical literature
[83-89]. Nephroblastomatosis, the presence of multiple
embryonic rests of tissue within the kidney that may give
rise to Wilms tumor, has been detected at autopsy in
infants with trisomy 18 who did not die from a Wilms
tumor [88-90].
Despite this biological origin, the average age of tumor
development is 5 years, ranging from 12 months to 13
years, later than it occurs in general population, suggest-
ing a different biological basis for the tumor in trisomy
18 children [12]. The prognosis is variable.
A child with trisomy 18 has an estimated risk to
develop Wilms tumor of about 1% [86]. Because of this
high risk, periodic screening with abdominal ultrasound
is recommended [48] (see “Health supervision and
management of medical problems” for more details).
Seven cases of association between trisomy 18 and
hepatoblastoma have been reported [91-97]. The age of
diagnosis ranged from 4 months to 3 years. The prog-
nosis was variable: surgical treatment was performed in
three patients, two of them were alive without evidence
of recurrence at 3 and 4 years of age [93-95], the other
died from progression of the tumor [94]. Among the
untreated patients, two died of cardiac failure (in one of
these hepatoblastoma was an incidental finding at
the autopsy) [92-96] and two from progression of the
tumor [93,96].
Neurologic
Several structural abnormalities of the central nervous
system have been reported in trisomy 18; the most
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callosum, microgyria, hydrocephalus and myelomenin-
gocele, present in about 5% of infants [12,75]. Functional
neurologic features include hypotonia in infancy, hyper-
tonia in older children, central apnea and seizures,
occurring in 25-50% of children but usually easy to con-
trol with pharmacological therapy [12]. Central apnea is
one of the principal causes of early death [3,4]. A recent
paper described an infant with trisomy 18 and apneic
episodes representing complex partial seizures success-
fully treated with zonisamide [98].Figure 3 This girl, now 16 years of age and very healthy, had a
ventricular septal defect repair as an infant; she is shown
here at various ages enjoying a favorite pastime and feeding
herself. She is walking with assistance but can climb stairs on
her own.Developmental and behavior
In older children with trisomy 18 significant develop-
mental delay is always present ranging from a marked to
profound degree of psychomotor and intellectual disabil-
ity. There is not a regression, but a stable status with
slow gaining of some skills. In the most cases expressive
language and independently walk are not achieved, but
some older children can use a walker [99]. There is also
one report of a 4-year-old child with full trisomy 18 who
could walk independently [100]. While developmental
age in older children is 6-8 months overall, most have
some skills of older children, including sleeping inde-
pendently, self-feeding, imitating, using a sign board, fol-
lowing simple command, and understanding cause and
effect [99]. All children acquire abilities such as recog-
nizing their family and smiling appropriately [99]. (See
Figures 2 and 3). Recognizing the significant delays, Baty
et al., state in their article describing developmental
skills in older children with trisomy 18 (and 13) “ Older
children could use a walker, understand words and
phrases, use a few words or signs, crawl, follow simple
commands, recognize and interact with others and play
independently” [99]. Thus children with trisomy 18,
while showing marked developmental and cognitive dis-
ability have many more abilities than usually perceived
in the stereotype and prior portrayals of the condition
(Figures 2 and 3).Figure 2 A young lady with full trisomy 18 in early childhood
and in adolescence; she lived to 19 years of age and achieved
multiple milestones, including sitting and walking in a walker.As mentioned above (see “Etiology and Pathogenesis”)
among patients with mosaic trisomy 18 the phenotype is
extremely variable, and there is no correlation between
the percentage of trisomy 18 cells in either blood cells
or skin fibroblasts and the severity of intellectual disabil-
ities [24].
Health supervision and management
After the discharge from the hospital, follow-up visits
for health supervision should be regular and often in the
first weeks and months of life; referral to the appropriate
pediatric subspecialists can occur. In the long-survival
children, the frequency of health supervision visits may
decrease as they advance, depending on the specific
needs of each child.
Generally, children with trisomy 18 should receive the
same routine care, e.g., anticipatory guidance and immu-
nizations that all children receive. In regards to adminis-
tering immunizations, the weight and overall status of
an infant, in particular the presence of a seizure disorder,
should be taken into consideration. Decisions surround-
ing the treatment of specific problems should be decided
upon with the parents and medical team according to
the degree of the involvement and what is in the best
interest of the child [49].
Table 3 summarizes the schedule of clinical and
laboratory/referrals at the time of birth or diagnosis and
during the follow up periods. These are modeled after
other recent guidelines for the routine care of children
with rare diseases.
Growth and feeding
Growth parameters (weight, length and head circumfer-
ence) should be checked during each evaluation, more
frequently in the first weeks and months of life, and
plotted on the specific growth charts [49].
Table 3 Guidelines for routine evaluation in children with trisomy 18 at time of diagnosis and during follow up
Area of clinical evaluation Time Assessment
Growth and feeding every visit Use published growth curves, investigate need
for enteral nutrition
Psychomotor and cognitive developmental progress every visit developmental delay and referral to early
intervention program and PT/OT
Neurologic exam every visit muscular tone abnormalities, seizures, referral
to neurology if needed
Cardiology and echocardiogram at birth/diagnosis – follow up as needed congenital heart defect, pulmonary hypertension
Abdominal ultrasound at birth/diagnosis - follow up as needed renal malformation
every 6 months until adolescence Wilms tumor and hepatoblastoma
Ophthalmology at birth/diagnosis eye malformations
older children photophobia and refractive defects, prescribe
sunglasses as needed
Audiology at birth/diagnosis - follow up as needed sensorineural hearing loss
Orthopedic exam every visit in children older than 2 years scoliosis
Gastroenterology if needed gastroesophageal reflux, need of enteral nutrition
Pulmonology if needed recurrent pulmonary infections, central and
obstructive apnea
Sleep study if needed central and obstructive apnea
Adapted from Carey [12].
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with a radiographic swallow study can be useful if
needed to consider the ability of the child to protect
the airway; use of feeding tube in neonatal period or
placement of gastrostomy can be considered to assure
appropriate and safe feeding. Referral to a feeding or
dysphagia team is an option.
Gastroesophageal reflux should be considered as a
potential factor in feeding problems. If needed, standard
medical therapy may be started. If medical treatment is
not successful, surgery can be considered [12].
Cardiovascular
At the time of diagnosis or in the newborn period car-
diac evaluation including echocardiogram should be
performed. Traditionally, heart defects in trisomy 18
patients have been managed conservatively. Since 1990s
few reports of cardiac surgery in this population has
been published [49,58], but recently four studies on
larger series of patients appeared in the medical litera-
ture [76-79]. These investigations showed that most
patients (82-91%) with trisomy 18 can survive palliative
and corrective heart surgeries and can be discharged
from the hospital [76,77]. In one study from Japan the
median postoperative survival reported was 179 days,
and the median survival for this group of patients was
324 days [76]. In the same study, the most frequent
cause of death was infections; otherwise heart failure
was the cause of death in only one patient, suggesting
that cardiac surgery is effective in preventing congenital
heart defect-related death [76]. Therefore, the authorsconcluded that intensive care, including optional cardiac
surgery, in selected patients with trisomy 18 is ethically
acceptable [79].
In a recent investigation Yamagishi et al., [78] suggests
that surgery should be considered in trisomy 18 infants
because it may improve life expectancy, facilitate dis-
charge from the hospital, and improve quality of life of
both patient and family. The author qualifies the recom-
mendation in stating that the risk of surgery in patients
with trisomy 18 is higher than in patients without tri-
somy 18 or in patients with trisomy 21, and acknowl-
edges that it is still unknown whether the cardiac
surgery improves the long-term prognosis of trisomy
18 children.
Recently Maeda et al. reported the results of a nation-
wide questionnaire-based study made by the Japanese
Society of Pediatric Cardiology and Cardiovascular Sur-
gery [79]. They collected and evaluated clinical data
from 134 patients with trisomy 18: 94% of patients
had congenital heart defects, the most frequent one was
ventricular septal defect (59%) and 52% of patients
developed pulmonary hypertension. Twenty-five percent
of patients with congenital heart defects underwent
cardiac surgery, and 56% of these patients have survived
beyond postoperative period. In most patients pallia-
tive surgery was performed, but 19% of children under-
went intracardiac repair for ventricular septal defect.
Operated patients survived longer than those who did
not have surgery.
The severity of cardiac defect and the indications
for pharmacological or surgical treatment differ among
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ation considering the overall health state of the infant is
needed to determine optimal treatment [78].
These above stated approaches and views that lead to
the option of cardiac surgery are controversial as
reflected in the paper cited above by Janvier et al. [70]
and in the more recently comprehensive review of the
topic by Merritt et al. [101]. In this latter article the
authors summarize much of the previous literature on
the ethical and legal aspects of care and recommend a
palliative care model in the care of infants with trisomy
18 (and trisomy 13). We will discuss this theme more
below in the section on Unresolved Questions.Respiratory
Evaluation by a pulmonologist can be performed if
respiratory problems become important, especially in
the infant where it is difficult to sort out the various fac-
tors that might be playing a role, i.e., upper airway
obstruction, pulmonary hypertension and central apnea.
Evaluations do not differ from those in other children
with similar symptoms. Sleep study can be useful to
detect the severity of sleep apnea problems. Decisions
about home monitoring and oxygen therapy should be
made with parents on an individual basis [12].
In recent years there appears to be an increase in
therapeutic procedures including tracheostomy place-
ment in children with trisomy 18 [102] (see Figure 1).
Also of note the web page of the Support Organization
of Trisomy 18, 13, and Related Disorders, maintains and
updates a registry of surgical procedures (including heart
and tracheostomies) documented in children with tri-
somy 18 (www.trisomy.org). As in all decision-making in
the care of infants with trisomy 18, parents and physi-
cians make these choices when the intervention is in the
best interest of the child.
Administration of palivizumab for the prevention of
RSV lower respiratory tract disease should be considered
in infants with trisomy 18 even those without congenital
heart defects.Ophthalmologic
Ophthalmologic evaluation is recommended to detect
common structural abnormalities and, in older children,
visual acuity defects [12]. When needed, treatment of
eye defects is the same as in other children. In older
infants with photophobia sunglasses are usually helpful.Ears and hearing
Audiological evaluation is recommended in all infants; if
sensorineural hearing loss is detected, the use of hearing
aids can be offered and attempted [12].Musculoskeletal
In children older than 2 years, clinical evaluation of the
spine should be performed at each health supervision
visit, followed by spine X-ray and specialist evaluation if
scoliosis is clinically suspected. Sometimes, in older chil-
dren, surgery for severe scoliosis should be considered
because of consequent restrictive lung disease.
The decision about treatment of clubfoot in infants
(with cast or surgery) is complex, because only a small
percentage of children with trisomy 18 can walk assisted
or independently.
Genitourinary
Abdominal ultrasound screening is recommended in
children with trisomy 18.
If renal abnormalities are detected, follow up for
urinary infection and renal failure by periodic blood and
urine analysis should be performed. The treatment
of urinary infections does not differ from that in any
other child.
Neoplasia
The high incidence of intra-abdominal tumors, particu-
larly Wilms tumor and hepatoblastoma, in trisomy 18
children justifies the recommendation of abdominal
sonographic screening in these patients. There is no
established timing for the screening, but it may be
started after 6 months of life with a screening every 6
months and continued into adolescence because one of
the cases of Wilms tumor reported developed in a
13-year-old female [12,87].
Neurologic
Neurological evaluation is recommended in all trisomy
18 patients. Usually they need physical therapy for tone
muscle abnormalities. Management of epilepsy is similar
to that in other children; seizures are generally well con-
trolled by standard pharmacological therapy.
Developmental and behavior
At each health supervision visits assessment of develop-
mental progression through standard developmental
evaluation is mandatory, and early referral to interven-
tion programs and physical therapy is recommended.
Overall care and ongoing support
The key ingredient in carrying out effective health
supervision in the care of infants and children with tri-
somy 18 is a committed primary care practitioner. As
pointed out by Carey [48] a clinician who is willing to
oversee the care and provide ongoing support to the
family should not be hesitant to take on the challenge
of shepherding the management of a child with this
disorder (despite its relative rareness) and providing
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to a palliative care team can aid in the needed on-
going support and be a good resource for the family
and clinician.
Unresolved questions
As mentioned above the most clearly unresolved issue
is the controversy surrounding the option of aggressive
respiratory or surgical treatment of infants with trisomy
18. In this concluding section we will try to provide
some perspective on this highly complex topic.
Because of the high neonatal and infant mortality and
because of the issue usually described as the quality of
life in children with the syndrome, many practitioners in
the US and Europe have argued for a noninterventionist
approach with accompanying comfort care (sometimes
called custodial) and currently with the guidance of a
palliative care team [101]. This view was articulated by
Bos et al and Paris et al. [65,66] and discussed in detail
most recently by Janvier et al. [70] and Merritt et al.
[101] as mentioned above. The conventional view at
least among US neonatologists is reflected in the survey
study by McGraw and and Perlman where 55% of the
physicians polled stated that they would not resuscitate
a newborn in the delivery room known to have trisomy
18 and a ventricular septal defect [68]. The Ethics
Rounds paper by Janvier et al. [70] comprehensively
summarizes all of the themes that emerge in any discus-
sion of care in a baby with trisomy 18. These themes
include the following: the best interest of the child
standard, parent autonomy, allocation of resources, qual-
ity of life of children with trisomy 18, and the potential
pain and suffering experienced if treatment occurs for
the child. In the recent paper by Merritt et al. [101], the
authors provide an even more referenced review of the
important themes of the topic. These authors present a
list of questions to consider in the setting of a prenatal
and postnatal diagnosis of trisomy 18 (and 13). They
close their paper with a poignant assertion, “We assert
that transforming hope for cure to hope for the child
and the family to be relieved from suffering, and to
experience love and care in their infant’s lifetime, should
be the primary goal.” The authors could not agree more.
However, Merritt et al. consistently use the descriptor
“lethal” throughout the paper. They, like the authors
of many of their cited papers, perceive trisomy 18 as “le-
thal” when in fact at least 1 in 20 infants survive the first
year of life even with modern day approaches, which
tend to be comfort care and non-intervention [71].
In an Invited Comment Kosho [103] reflected on the
varied views in Japan on the care of infants with trisomy
18. This author summarized a series of guidelines for
parents and providers in determining choices around
the medical care of serious newborn conditions of whichtrisomy 18 represents the prototype. These guidelines
along with the tables published in the Merritt et al.
paper [101] go a long way in initiating needed dialogue
and guidelines on this theme.
What is missing in both the Janvier et al. Ethics
Rounds [70] and in the Merritt et al. treatise [101] are
two themes: 1. clarification of 5-8% infant survival,
(which is clearly documented in the figures from mul-
tiple population studies cited in the this paper), and 2.
the complete picture of quality of life, which is known
only from perusal of the parents support group websites
[see Table 2, SOFT US and UK], the papers by Baty
et al., [49,101], and the recent article by Janvier et al.
where the authors report parents’ positive experiences in
rearing a child with trisomy 18 (and 13) [104].
Let us reiterate these themes: 1. As indicated 5-8% of
infants with trisomy 18 without special care live to their
first birthday; thus as pointed out by Wilfond and the se-
nior author (JCC), “lethal” is a misplaced and misleading
description [70]; 2. Parents and families of children with
trisomy 18 cope well, appreciate a unique quality of life
in their children, value their children deeply, and want
to be a part of the decisions made around care. In a
study of a web-based survey Janvier et al. documented
this experience in over 300 families coping with the
challenges of parenting children with trisomy 18 inter-
nationally [105]. Fenton [105] also related his experience
as a palliative care specialist and expanded the tradition-
ally narrowed view of quality of life in children and their
parents with trisomy 18 (and 13). Bruns [106] articulated
these themes in a recent article that reports on parent-
reported data.
There is no simple solution to this dilemma and con-
troversy. Certainly more qualitative and quantitative
data on the experience of families are needed. Their
voice - while reflecting one aspect of the whole portrait -
is crucial and vital. Secondly, international consensus on
guidelines for care that includes all of the specialties
involved in the care of fetuses, newborns, and older chil-
dren with trisomy 18 is required. (The authors are cur-
rently organizing such a consensus group). Thirdly,
as suggested by Wilfond and Carey [73], avoidance of
the use of the term “lethal.” Continuation of the now
ongoing dialogue on this topic by pediatricians, geneti-
cists, bioethicists, families, and the appropriate care spe-
cialists is mandatory and welcomed. In a recent opinion
piece one of us (JCC) reviewed this emerging dialogue
surrounding treatment issues in trisomy 18 (and 13); the
reader is referred to that paper for additional discussion
of the themes and controversies [107].Competing interest
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